RecruitingNCT06628661

Ten-Year Outcomes of Operable Solitary Hepatocellular Carcinoma Patients: Impact of Tumor Size Over 6.5 Cm and Microvascular Invasion


Sponsor

Chang Gung Memorial Hospital

Enrollment

3,000 participants

Start Date

Sep 30, 2024

Study Type

OBSERVATIONAL

Conditions

Summary

The goal of this study is to evaualte the impact of tumor size and microvascular invasion among patients with solitary hepatocellualr carcinoma and post operation. The main questions it aims to answer are: Does the tumor size have more impact on the survival and recurrence than microvascular invasion among solitary operable hepatocellular carcinoma patients? Researchers will retrospectively analyze the prospectively collected clinical database during January 2022 and December 2019 to see whether tumor size more than 6.5 cm or microvascular invasion. The solitary operable hepatocellular carcinoma patients would be classified based on the status of microvascular invasion and tumor size, and the outcome would be evaluated among different sub-populations of the feasible subjects.


Eligibility

Min Age: 18 YearsMax Age: 80 Years

Inclusion Criteria1

  • Operable solitary hepatocellular carcinoma

Exclusion Criteria3

  • Not pT1N0M0 or pT2N0M0
  • Missing tumor size
  • Errors in survival/recurrence dates or status

Interventions

PROCEDURESurgery for HCC larger than 6.5 cm

Surgery for HCC larger than 6.5 cm without mVI

PROCEDURESurgery for HCC larger than 2 cm

Surgery for HCC larger than 2 cm with mVI


Locations(1)

Chang Gung Medical Foundation

Taoyuan District, Taiwan

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06628661


Related Trials